Endocrine Physiology (Adrenal, Thyroid, Pituitary)

Answer Card

Endocrine physiology encompasses the integrated function of the hypothalamic-pituitary axis and its target organs (adrenal, thyroid, gonads), which regulate metabolism, stress response, fluid/electrolyte balance, and growth. Key concepts include hormone synthesis, negative feedback regulation, receptor mechanisms, and critical illness-induced endocrine dysfunction.

Core Principles:

• Hypothalamic-pituitary axis: Hypothalamic releasing hormones (CRH, TRH, GnRH, GHRH) control anterior pituitary hormone secretion; dopamine tonically inhibits prolactin
• Adrenal cortex: Zona glomerulosa (aldosterone/mineralocorticoids), zona fasciculata (cortisol/glucocorticoids), zona reticularis (androgens); controlled by ACTH and RAAS
• Adrenal medulla: Chromaffin cells produce catecholamines (80% epinephrine, 20% norepinephrine) under sympathetic control
• Thyroid axis: TRH → TSH → T4/T3; T4 is the prohormone, T3 is the active hormone; deiodinases regulate peripheral conversion
• Hormone transport: Protein-bound hormones are inactive; free hormone mediates biological effects
• Euthyroid sick syndrome: Adaptive response to critical illness with low T3, normal/low T4, normal TSH; treatment not recommended
• Critical illness-related corticosteroid insufficiency (CIRCI): Inadequate cortisol response to stress despite high serum levels; may benefit from stress-dose hydrocortisone

---

Clinical Overview

Endocrine physiology is fundamental to understanding the stress response in critical illness, metabolic regulation, and the effects of intensive care interventions. The hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-thyroid (HPT) axis are among the most clinically relevant endocrine systems in intensive care medicine, influencing haemodynamic stability, metabolic homeostasis, and patient outcomes.

The hypothalamus functions as the master integrator of endocrine function, receiving neural inputs from the limbic system, brainstem, and cortex, and translating these into hormonal signals via releasing and inhibiting hormones. These hormones travel through the hypothalamic-hypophyseal portal system to the anterior pituitary, where they regulate the synthesis and release of tropic hormones. The posterior pituitary, in contrast, releases hormones (vasopressin and oxytocin) synthesised in hypothalamic nuclei and transported axonally.

The adrenal gland is critical for the stress response, producing cortisol (the primary glucocorticoid), aldosterone (the primary mineralocorticoid), and catecholamines. In critical illness, the HPA axis is activated to support cardiovascular function, mobilise energy substrates, and modulate the immune response. However, prolonged critical illness can lead to relative adrenal insufficiency or critical illness-related corticosteroid insufficiency (CIRCI), characterised by inadequate cortisol response despite high serum levels (PMID: 28848065).

Thyroid hormones regulate basal metabolic rate, thermogenesis, and cardiovascular function. The euthyroid sick syndrome (non-thyroidal illness syndrome) is a common adaptive response to critical illness, characterised by low T3, variable T4, and normal/low TSH. This represents a protective mechanism to conserve energy during acute illness, and treatment with thyroid hormone replacement is generally not recommended and may be harmful (PMID: 28336049).

Understanding these endocrine systems is essential for CICM First Part candidates, as questions frequently address hormone synthesis, transport, receptor mechanisms, negative feedback, and the pathophysiology of critical illness-related endocrine dysfunction.

---

CICM Exam Focus

First Part Written (SAQ/MCQ)

Common SAQ Stems:

• Describe the hypothalamic-pituitary-adrenal axis, including negative feedback mechanisms
• Outline the synthesis and transport of thyroid hormones
• Describe the actions of cortisol and its regulation
• Outline the mechanism and clinical significance of euthyroid sick syndrome
• Describe the structure and function of the adrenal medulla

Key Concepts for MCQs:

• Hormone synthesis pathways (steroidogenesis, thyroid hormone synthesis)
• Protein binding and free hormone hypothesis
• Receptor mechanisms (nuclear receptors, G-protein coupled receptors)
• Negative feedback at multiple levels
• Deiodinase enzyme functions

First Part Viva Topics

High-Yield Viva Themes:

1. Draw and explain the HPA axis with feedback mechanisms
2. Describe cortisol synthesis and its rate-limiting steps
3. Explain the cellular actions of thyroid hormones
4. Discuss the pathophysiology of euthyroid sick syndrome
5. Compare and contrast catecholamine synthesis and actions
6. Describe the regulation of aldosterone secretion
7. Explain the concept of hormone permissiveness

Second Part Application

Clinical Scenarios:

• Septic shock with refractory hypotension (CIRCI, stress-dose steroids)
• Thyroid storm in ICU (diagnosis, treatment, beta-blockade)
• Myxoedema coma (T4 vs T3 replacement, supportive care)
• Pituitary apoplexy (neurosurgical emergency, hormone replacement)
• Adrenal crisis (recognition, hydrocortisone dosing)
• Phaeochromocytoma crisis (alpha-blockade before beta-blockade)

---

Key Points

1. The hypothalamic-pituitary axis controls endocrine function through releasing hormones (CRH, TRH, GnRH, GHRH, somatostatin) and inhibiting hormones (dopamine), with negative feedback from target organ hormones
2. Cortisol is synthesised in the zona fasciculata under ACTH control; cholesterol side-chain cleavage by CYP11A1 is the rate-limiting step
3. Aldosterone is synthesised in the zona glomerulosa, primarily regulated by angiotensin II and potassium, not ACTH
4. Catecholamines are synthesised in chromaffin cells via tyrosine → DOPA → dopamine → norepinephrine → epinephrine pathway; PNMT (requires cortisol) catalyses the final step
5. Thyroid hormone synthesis requires iodide trapping (NIS), thyroglobulin, TPO, and coupling of MIT/DIT; T4 is the predominant secretory product
6. T3 is the active hormone (10× more potent than T4); peripheral conversion by deiodinases is critical
7. Type 1 deiodinase (D1) converts T4→T3 in liver/kidney; inhibited in critical illness (explains low T3 in euthyroid sick syndrome)
8. Type 3 deiodinase (D3) converts T4→rT3 and T3→T2 (inactivation); upregulated in critical illness
9. Euthyroid sick syndrome is characterised by low T3, low/normal T4, normal/low TSH, and elevated rT3; treatment not recommended
10. CIRCI occurs in 10-20% of septic shock patients; random cortisol <10 µg/dL or delta cortisol <9 µg/dL after ACTH may indicate insufficiency

---

Hypothalamic-Pituitary Axis

Anatomy and Organisation

The hypothalamus is a small (4-5 g) region of the diencephalon located below the thalamus, forming the floor and walls of the third ventricle. It contains distinct nuclei with specific endocrine functions (PMID: 15207268):

Hypothalamic Nuclei and Functions:

The hypothalamic-hypophyseal portal system is a specialised vascular arrangement that delivers releasing hormones directly to the anterior pituitary at high concentrations. Blood flows from the superior hypophyseal artery to the primary capillary plexus in the median eminence, then via portal veins to the secondary capillary plexus in the anterior pituitary. This allows hormones to reach target cells at concentrations 10-100 times higher than systemic levels (PMID: 2139570).

The posterior pituitary (neurohypophysis) receives direct neural projections from hypothalamic nuclei. Vasopressin and oxytocin are synthesised in the supraoptic and paraventricular nuclei, packaged with neurophysins, and transported axonally to the posterior pituitary for release directly into the systemic circulation.

Anterior Pituitary (Adenohypophysis)

The anterior pituitary comprises five distinct cell types, each producing specific hormones under hypothalamic control (PMID: 27234218):

Anterior Pituitary Cell Types:

Proopiomelanocortin (POMC): ACTH is derived from the precursor POMC in corticotrophs. Proteolytic processing also yields β-lipotropin, β-endorphin, α-MSH, and CLIP. The specific cleavage pattern differs between the anterior pituitary (mainly ACTH, β-lipotropin) and intermediate lobe/hypothalamus (α-MSH, β-endorphin) (PMID: 23159877).

Hypothalamic Releasing and Inhibiting Hormones

Corticotropin-Releasing Hormone (CRH)

Structure: 41-amino acid peptide synthesised primarily in the paraventricular nucleus (PVN).

Regulation: CRH release is stimulated by stress (physical, psychological, inflammatory), circadian input from the suprachiasmatic nucleus, and various neurotransmitters (acetylcholine, serotonin, catecholamines). It is inhibited by cortisol negative feedback and GABA (PMID: 11108596).

Mechanism: CRH binds to CRH-R1 (Gs-coupled) on corticotrophs, activating adenylyl cyclase and increasing cAMP. This stimulates POMC gene transcription and ACTH release. Vasopressin (AVP) acts synergistically with CRH via V1b receptors (Gq-coupled, phospholipase C pathway).

Circadian Rhythm: CRH/ACTH/cortisol exhibit a robust circadian pattern with peak levels at 06:00-08:00 (nadir at midnight). This rhythm is driven by the suprachiasmatic nucleus and is disrupted in critical illness, shift work, and jet lag (PMID: 21346785).

Stress Response: Acute stress causes rapid CRH release (seconds to minutes). Chronic stress leads to sustained HPA axis activation with potential adrenal hypertrophy and altered feedback sensitivity.

Thyrotropin-Releasing Hormone (TRH)

Structure: Simple tripeptide (pyroglutamyl-histidyl-prolinamide) synthesised in the PVN.

Mechanism: TRH binds to TRH-R (Gq-coupled) on thyrotrophs, activating phospholipase C and increasing intracellular calcium. This stimulates TSH synthesis and release. TRH also stimulates prolactin release from lactotrophs (PMID: 22275474).

Regulation: TRH is inhibited by T3 (direct feedback on PVN neurons) and somatostatin. It is stimulated by cold exposure (thermogenic response) and inhibited by fasting, illness, and glucocorticoids.

Clinical Relevance: TRH secretion is suppressed in critical illness, contributing to the central component of euthyroid sick syndrome. Exogenous TRH administration can restore TSH pulsatility but has not been shown to improve outcomes.

Gonadotropin-Releasing Hormone (GnRH)

Structure: 10-amino acid peptide synthesised in the preoptic area and arcuate nucleus.

Pulsatile Secretion: GnRH must be released in a pulsatile manner (every 60-120 minutes) to stimulate LH and FSH. Continuous GnRH administration paradoxically suppresses gonadotropin release by receptor downregulation (basis for GnRH agonist therapy in prostate cancer) (PMID: 25032734).

Mechanism: GnRH binds to GnRH-R (Gq-coupled) on gonadotrophs, activating phospholipase C. Pulse frequency determines FSH:LH ratio—faster pulses favour LH, slower pulses favour FSH.

Regulation: GnRH is modulated by kisspeptin neurons, which integrate metabolic and reproductive signals. Inhibited by sex steroids (negative feedback) except for positive feedback from estrogen at mid-cycle (LH surge).

Growth Hormone-Releasing Hormone (GHRH)

Structure: 44-amino acid peptide synthesised in the arcuate nucleus.

Mechanism: GHRH binds to GHRH-R (Gs-coupled) on somatotrophs, increasing cAMP and stimulating GH synthesis and release. Ghrelin (from stomach) also stimulates GH release via the GH secretagogue receptor (PMID: 21415850).

Regulation: GHRH release is pulsatile, with GH peaks during sleep (slow-wave sleep) and after exercise. Inhibited by somatostatin (GHIH), IGF-1, and GH itself.

Growth Hormone Actions: GH has both direct metabolic effects (lipolysis, glucose counter-regulation, protein synthesis) and indirect effects via IGF-1 (growth, anabolism). GH secretion decreases with age and is markedly suppressed in critical illness.

Somatostatin (Growth Hormone-Inhibiting Hormone)

Structure: 14-amino acid cyclic peptide (also 28-amino acid form) synthesised in the periventricular nucleus and widely distributed.

Mechanism: Somatostatin binds to SSTR1-5 (Gi-coupled), inhibiting adenylyl cyclase. It inhibits GH and TSH release from the pituitary. Also produced in the pancreatic delta cells (inhibits insulin and glucagon) and GI tract (inhibits multiple GI hormones) (PMID: 24530899).

Clinical Applications: Octreotide (somatostatin analogue) is used for acromegaly, carcinoid syndrome, variceal bleeding (splanchnic vasoconstriction), and chylothorax.

Dopamine (Prolactin-Inhibiting Factor)

Structure: Catecholamine neurotransmitter synthesised in tuberoinfundibular dopaminergic neurons of the arcuate nucleus.

Mechanism: Dopamine is released into the hypothalamic-hypophyseal portal system and tonically inhibits prolactin secretion via D2 receptors (Gi-coupled) on lactotrophs. This is the only hypothalamic hormone that is primarily inhibitory to its target pituitary cell (PMID: 25399374).

Clinical Relevance: Pituitary stalk compression or lesions interrupt dopamine delivery, causing hyperprolactinaemia. Dopamine agonists (bromocriptine, cabergoline) treat prolactinomas. Dopamine antagonists (metoclopramide, antipsychotics) cause hyperprolactinaemia.

---

Negative Feedback Regulation

Classical Negative Feedback

Endocrine axes are regulated by hierarchical negative feedback loops operating at multiple levels (PMID: 19022858):

Long-loop feedback: Target organ hormones (cortisol, T3/T4) inhibit both hypothalamic releasing hormone and pituitary tropic hormone secretion.

Short-loop feedback: Pituitary hormones inhibit their own hypothalamic releasing hormones.

Ultra-short-loop feedback: Hormones inhibit their own release from the same cell (autocrine regulation).

HPA Axis Feedback

Cortisol exerts negative feedback at both the hypothalamus and pituitary through glucocorticoid receptors (GR). The feedback mechanism involves:

1. Rapid (minutes): Non-genomic membrane effects reducing CRH and ACTH release
2. Intermediate (hours): Inhibition of POMC gene transcription
3. Delayed (days): Reduced CRH and ACTH synthesis

The hippocampus also contains glucocorticoid receptors and modulates HPA axis activity, explaining the link between chronic stress, cortisol, and hippocampal atrophy (PMID: 18676425).

HPT Axis Feedback

T3 is the primary feedback signal, acting on both hypothalamic TRH neurons and pituitary thyrotrophs. T4 is converted to T3 locally by type 2 deiodinase (D2) in the hypothalamus and pituitary, providing an internal T3 source even when circulating T3 is low (PMID: 24297018).

Set-Point Regulation: The HPT axis maintains a logarithmic relationship between TSH and free T4. Small changes in free T4 produce large changes in TSH (10-fold change in TSH for each 2-fold change in free T4), making TSH a highly sensitive indicator of thyroid status.

Critical Illness Effects on Feedback

Critical illness disrupts normal feedback mechanisms through:

1. Inflammatory cytokines (IL-1, IL-6, TNF-α) directly inhibit hypothalamic and pituitary function
2. Altered deiodinase activity (decreased D1, increased D3) changes peripheral hormone metabolism
3. Glucocorticoid resistance impairs cortisol feedback despite high levels
4. Altered binding proteins changes the relationship between total and free hormone levels
5. Reduced pulsatile secretion disrupts the normal pattern of hormone release

---

Adrenal Physiology

Anatomy and Blood Supply

The adrenal glands are paired endocrine organs located superomedial to the kidneys. Each weighs 4-5 grams and consists of a cortex (90% of gland volume) and medulla (10%). The right adrenal is pyramidal and lies posterior to the IVC; the left is crescentic and lies medial to the spleen (PMID: 21346785).

Blood Supply: The adrenals have a rich blood supply from three sources:

• Superior adrenal arteries (from inferior phrenic arteries)
• Middle adrenal arteries (from aorta)
• Inferior adrenal arteries (from renal arteries)

Venous drainage is via a single adrenal vein: right to IVC, left to left renal vein. The adrenal has the highest blood flow per gram of any organ (6-7 mL/g/min), reflecting its metabolic activity (PMID: 22728329).

Adrenal Cortex Zones

The adrenal cortex is organised into three distinct zones (GFR: "salt, sugar, sex"):

Zona Glomerulosa (Outer Zone)

Primary Product: Aldosterone (mineralocorticoid)

Regulation:

• Angiotensin II (primary stimulus) - via AT1 receptors
• Potassium (direct depolarisation of glomerulosa cells)
• ACTH (permissive role, minor stimulus)
• NOT regulated by hypothalamic-pituitary axis

Unique Features: Expresses aldosterone synthase (CYP11B2) but not 17α-hydroxylase, preventing glucocorticoid or androgen synthesis (PMID: 24530899).

Zona Fasciculata (Middle Zone)

Primary Product: Cortisol (glucocorticoid)

Regulation:

• ACTH (primary stimulus) - via MC2R (Gs-coupled)
• CRH → ACTH → Cortisol axis
• Circadian rhythm (peak 06:00-08:00)
• Stress response (rapid ACTH increase)

Unique Features: Largest zone (75% of cortex); cells arranged in radial columns; rich in lipid droplets containing cholesterol esters (PMID: 21346785).

Zona Reticularis (Inner Zone)

Primary Products: Androgens (DHEA, DHEA-S, androstenedione)

Regulation:

• ACTH (primary stimulus)
• Adrenarche occurs at age 6-8 years

Clinical Relevance: Provides 50% of androgens in women (testosterone is synthesised peripherally from adrenal precursors). Congenital adrenal hyperplasia causes shunting of precursors into androgen synthesis (PMID: 23159877).

Steroid Hormone Synthesis

Cholesterol Acquisition

Steroidogenic cells obtain cholesterol from:

1. LDL receptor-mediated uptake (primary source)
2. HDL receptor (SR-B1)-mediated uptake (backup)
3. De novo synthesis (minor)
4. Intracellular stores (cholesterol ester droplets)

Rate-Limiting Step

The transfer of cholesterol from the outer to inner mitochondrial membrane by StAR (Steroidogenic Acute Regulatory protein) is the rate-limiting step in steroidogenesis. StAR expression is rapidly induced by ACTH through cAMP signalling (PMID: 23159877).

Key Enzymes (Cytochrome P450s)

CYP11A1 (Cholesterol side-chain cleavage/P450scc): Converts cholesterol to pregnenolone in mitochondria. This is the first committed step in steroid synthesis.

CYP17 (17α-hydroxylase/17,20-lyase): In zona fasciculata and reticularis, adds 17α-hydroxyl group (for cortisol synthesis) or cleaves side chain (for androgen synthesis).

CYP21A2 (21-hydroxylase): Converts 17-hydroxyprogesterone to 11-deoxycortisol (cortisol pathway) or progesterone to 11-deoxycorticosterone (aldosterone pathway). Most common enzyme deficiency in congenital adrenal hyperplasia.

CYP11B1 (11β-hydroxylase): Converts 11-deoxycortisol to cortisol in zona fasciculata.

CYP11B2 (Aldosterone synthase): Converts corticosterone to aldosterone in zona glomerulosa (also has 18-hydroxylase and 18-oxidase activities).

3β-HSD (3β-hydroxysteroid dehydrogenase): Converts pregnenolone to progesterone; also converts DHEA to androstenedione.

Cortisol Physiology

Secretion and Transport

Daily Production: 15-25 mg/day cortisol under basal conditions; can increase 5-10 fold during stress (150-250 mg/day equivalent) (PMID: 28848065).

Protein Binding:

• 80-90% bound to corticosteroid-binding globulin (CBG/transcortin)
• 5-10% bound to albumin
• 5-10% free (biologically active)

CBG is an α-globulin synthesised in the liver. It binds cortisol with high affinity (Kd ~30 nM) but limited capacity (saturates at cortisol ~25 µg/dL). CBG levels decrease in critical illness (inflammation, liver disease), increasing the free:total cortisol ratio (PMID: 25580018).

Circadian Rhythm: Peak cortisol at 06:00-08:00 (15-25 µg/dL), nadir at midnight (2-5 µg/dL). This rhythm is lost in critical illness, Cushing's syndrome, and shift workers.

Cellular Actions

Cortisol exerts genomic and non-genomic effects:

Genomic (slow, hours to days):

• Cortisol diffuses into cells and binds cytoplasmic glucocorticoid receptor (GR)
• GR-cortisol complex translocates to nucleus
• Binds glucocorticoid response elements (GREs) in DNA
• Transactivation: Induces anti-inflammatory proteins (IκBα, lipocortin-1, GILZ)
• Transrepression: Inhibits pro-inflammatory transcription factors (NF-κB, AP-1)

Non-genomic (rapid, seconds to minutes):

• Membrane-associated GR signalling
• Ion channel modulation
• Rapid cardiovascular effects (PMID: 19022858)

Metabolic Effects

Carbohydrate Metabolism:

• Stimulates gluconeogenesis (PEPCK, glucose-6-phosphatase induction)
• Promotes hepatic glycogen synthesis
• Causes peripheral insulin resistance (anti-insulin effect)
• Net effect: Increased blood glucose

Protein Metabolism:

• Inhibits protein synthesis in muscle
• Stimulates protein catabolism (amino acid mobilisation)
• Amino acids provide substrate for gluconeogenesis
• Causes muscle wasting with chronic excess

Fat Metabolism:

• Stimulates lipolysis (permissive effect with catecholamines)
• Promotes fat redistribution (central > peripheral in Cushing's)
• Fatty acids provide energy substrate

Cardiovascular Effects

Vascular Responsiveness: Cortisol is permissive for catecholamine action, maintaining vascular sensitivity to norepinephrine and epinephrine. This occurs through:

• Upregulation of α1-adrenergic receptors
• Inhibition of catecholamine-degrading enzymes (COMT, MAO)
• Reduced nitric oxide synthesis
• Decreased prostaglandin production

Cardiac Effects: Cortisol maintains cardiac contractility and output; deficiency causes hypotension and shock (PMID: 28848065).

Immune and Anti-inflammatory Effects

Cortisol is the most potent endogenous anti-inflammatory agent:

• Inhibits phospholipase A2 (via lipocortin-1), blocking arachidonic acid release
• Reduces prostaglandin and leukotriene synthesis
• Suppresses cytokine production (IL-1, IL-6, TNF-α)
• Inhibits leukocyte migration and adhesion
• Induces lymphocyte apoptosis
• Reduces histamine release from mast cells

These effects explain both the therapeutic utility and the infection susceptibility with glucocorticoid therapy (PMID: 23159877).

Aldosterone Physiology

Regulation of Secretion

Angiotensin II (primary regulator): Angiotensin II from the RAAS binds AT1 receptors (Gq-coupled) on zona glomerulosa cells, activating phospholipase C and increasing intracellular calcium. This stimulates aldosterone synthesis and release.

Potassium: Hyperkalaemia directly depolarises glomerulosa cells, opening voltage-gated calcium channels and stimulating aldosterone release. This provides a direct feedback loop for potassium homeostasis independent of RAAS (PMID: 23846770).

ACTH: Has a minor, permissive role in aldosterone synthesis. ACTH stimulates early steroidogenic steps but is not the primary regulator. Chronic ACTH excess causes mild hyperaldosteronism.

Natriuretic Peptides: ANP and BNP inhibit aldosterone secretion, providing a counterregulatory mechanism in volume expansion.

Mechanism of Action

Aldosterone binds the mineralocorticoid receptor (MR), a nuclear receptor expressed in the distal nephron (principal cells), colon, salivary glands, and sweat glands.

Renal Effects:

• Increases ENaC (epithelial sodium channel) expression and activity
• Increases Na⁺/K⁺-ATPase activity on basolateral membrane
• Increases ROMK (renal outer medullary potassium channel) activity
• Net effect: Sodium reabsorption, potassium and hydrogen ion secretion

Cardiovascular Effects:

• MR activation in heart causes fibrosis and remodelling
• Vascular MR causes endothelial dysfunction
• Blocked by spironolactone/eplerenone (mortality benefit in heart failure)

Cortisol and MR Selectivity

Cortisol has equal affinity for MR as aldosterone and circulates at 100-1000× higher concentrations. MR selectivity for aldosterone is achieved by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which converts cortisol to cortisone (inactive at MR) in aldosterone target tissues.

Liquorice (glycyrrhizic acid) inhibits 11β-HSD2, allowing cortisol to activate MR → apparent mineralocorticoid excess (hypertension, hypokalaemia) (PMID: 11756141).

Adrenal Medulla

Anatomy and Development

The adrenal medulla is embryologically derived from neural crest cells (same as sympathetic ganglia). It functions as a specialised sympathetic ganglion without postganglionic fibres—chromaffin cells release hormones directly into the circulation.

Chromaffin cells are arranged in clusters around central veins. Blood flows centripetally from the cortex through the medulla, exposing chromaffin cells to high cortisol concentrations (10-100× systemic levels). This "corticomedullary portal system" is essential for epinephrine synthesis (PMID: 23159877).

Catecholamine Synthesis

The catecholamine synthesis pathway occurs in chromaffin cells:

Tyrosine → L-DOPA (Tyrosine hydroxylase, rate-limiting step)

• Requires O₂, tetrahydrobiopterin (BH4), Fe²⁺
• Inhibited by catecholamines (product feedback)

L-DOPA → Dopamine (DOPA decarboxylase/aromatic amino acid decarboxylase)

• Requires pyridoxal phosphate (vitamin B6)

Dopamine → Norepinephrine (Dopamine β-hydroxylase)

• Located in chromaffin granule membrane
• Requires Cu²⁺, ascorbic acid

Norepinephrine → Epinephrine (Phenylethanolamine N-methyltransferase, PNMT)

• Located in cytoplasm of adrenal chromaffin cells only
• Requires S-adenosylmethionine (SAM) as methyl donor
• Induced by cortisol (explains why 80% of adrenal catecholamines are epinephrine)

The cortisol induction of PNMT explains why the adrenal medulla (but not sympathetic ganglia) produces predominantly epinephrine (PMID: 11756141).

Catecholamine Storage and Release

Catecholamines are stored in chromaffin granules with:

• Chromogranins (binding proteins)
• ATP (co-released, marker of secretion)
• Dopamine β-hydroxylase

Release Mechanism: Acetylcholine from preganglionic sympathetic fibres binds nicotinic receptors on chromaffin cells, causing calcium influx and exocytosis of granule contents. This is an example of stimulus-secretion coupling (PMID: 21560595).

Secretion Pattern: The adrenal medulla releases ~80% epinephrine and ~20% norepinephrine. Sympathetic nerve terminals release only norepinephrine. Plasma epinephrine is primarily from adrenal medulla; plasma norepinephrine is from both sympathetic nerves (80%) and adrenal (20%).

Catecholamine Metabolism

Catecholamines are rapidly metabolised (half-life 1-2 minutes) by:

COMT (Catechol-O-methyltransferase): Adds methyl group, produces metanephrines (metanephrine from epinephrine, normetanephrine from norepinephrine)

MAO (Monoamine oxidase): Oxidatively deaminates catecholamines and metanephrines

Final Product: Vanillylmandelic acid (VMA) excreted in urine (main metabolite for 24-hour collection). Plasma and urinary metanephrines are more sensitive for phaeochromocytoma diagnosis (PMID: 25096401).

Adrenergic Receptors

Alpha-1 Receptors (Gq-coupled):

• Vascular smooth muscle contraction (vasoconstriction)
• Pupil dilation (mydriasis)
• Sphincter contraction (GI, bladder)

Alpha-2 Receptors (Gi-coupled):

• Presynaptic inhibition of norepinephrine release
• Platelet aggregation
• Sedation (central α2 in locus coeruleus)

Beta-1 Receptors (Gs-coupled):

• Increased heart rate (chronotropy)
• Increased contractility (inotropy)
• Increased AV conduction (dromotropy)
• Renin release from kidney

Beta-2 Receptors (Gs-coupled):

• Bronchodilation
• Vasodilation (skeletal muscle)
• Glycogenolysis
• Relaxation of uterine smooth muscle

Beta-3 Receptors (Gs-coupled):

• Lipolysis in adipose tissue
• Thermogenesis

Epinephrine has higher affinity for β2 receptors than norepinephrine; both have similar affinity for α and β1 receptors (PMID: 21560595).

---

Thyroid Physiology

Anatomy and Blood Supply

The thyroid gland is a butterfly-shaped organ weighing 15-25 grams, located anterior to the trachea at C5-T1 level. It consists of two lobes connected by an isthmus. The pyramidal lobe (embryonic remnant) is present in 50% of individuals.

Blood Supply: The thyroid has one of the highest blood flows per gram of any organ:

• Superior thyroid arteries (from external carotid)
• Inferior thyroid arteries (from thyrocervical trunk)
• Occasionally thyroidea ima (from aortic arch or brachiocephalic)

Venous drainage is via superior, middle, and inferior thyroid veins. Lymphatic drainage follows the blood vessels to pretracheal, paratracheal, and deep cervical nodes (PMID: 22275474).

Thyroid Hormone Synthesis

Follicular Structure

The thyroid consists of follicles lined by follicular cells (thyrocytes) surrounding colloid (stored thyroglobulin). Each follicle is 50-500 µm in diameter and functions as an independent unit.

Parafollicular cells (C cells) are scattered between follicles and produce calcitonin. They are derived from neural crest and are the cell of origin for medullary thyroid cancer.

Iodine Metabolism

Iodine Requirements: 150 µg/day (adult), 250 µg/day (pregnancy). Iodine deficiency is the most common preventable cause of mental retardation worldwide (PMID: 24297018).

Iodide Trapping: The sodium-iodide symporter (NIS) on the basolateral membrane of thyrocytes actively transports iodide against a 20-40:1 concentration gradient. NIS is stimulated by TSH and inhibited by iodide excess (Wolff-Chaikoff effect).

Iodide Oxidation: Iodide is oxidised to iodine (I⁰) or iodonium (I⁺) by thyroid peroxidase (TPO) at the apical membrane using H₂O₂ as oxidant.

Thyroglobulin and Hormone Synthesis

Thyroglobulin (Tg): Large glycoprotein (660 kDa) synthesised by thyrocytes and secreted into colloid. Contains ~70 tyrosine residues, approximately 25% of which are available for iodination.

Organification: TPO iodinates tyrosine residues in thyroglobulin:

• Monoiodotyrosine (MIT): One iodine atom
• Diiodotyrosine (DIT): Two iodine atoms

Coupling: TPO catalyses the coupling of iodinated tyrosines within thyroglobulin:

• MIT + DIT → T3 (triiodothyronine)
• DIT + DIT → T4 (tetraiodothyronine/thyroxine)

The T4:T3 ratio in thyroglobulin is approximately 15:1, reflecting the predominance of T4 synthesis (PMID: 28336049).

Propylthiouracil (PTU) and Methimazole: Inhibit TPO, blocking organification and coupling. PTU also inhibits peripheral T4→T3 conversion (D1 inhibition).

Hormone Release

TSH stimulates pinocytosis of colloid by thyrocytes. Colloid droplets fuse with lysosomes containing proteases that cleave thyroglobulin, releasing T4, T3, MIT, and DIT. T4 and T3 are released into the circulation; MIT and DIT are deiodinated intracellularly with iodine recycling.

Daily Thyroid Secretion:

• T4: 80-100 µg/day (100% from thyroid)
• T3: 30-40 µg/day (20% from thyroid, 80% from peripheral conversion)

Thyroid Hormone Transport

Thyroxine-Binding Globulin (TBG): Binds 70% of circulating T4 and T3; high affinity, low capacity. Synthesised in liver; increased by estrogen, decreased by androgens and liver disease.

Transthyretin (TTR/Prealbumin): Binds 10-15% of T4; also transports retinol. Decreased in malnutrition and critical illness (negative acute phase protein).

Albumin: Binds 15-20% of T4; low affinity, high capacity. Decreased in nephrotic syndrome and liver disease.

Free Hormone Fraction:

• Free T4: 0.02-0.03% of total T4
• Free T3: 0.3-0.5% of total T3

The free hormone hypothesis states that only free (unbound) hormone enters cells and mediates biological effects. Changes in binding proteins alter total hormone levels but not free hormone or clinical status (except in extreme cases) (PMID: 25726649).

Peripheral Conversion and Deiodinases

T4 is a prohormone; T3 is the active hormone with 10× greater affinity for thyroid hormone receptors. Peripheral tissues convert T4 to T3 using deiodinase enzymes (PMID: 24297018):

Type 1 Deiodinase (D1):

• Location: Liver, kidney, thyroid
• Function: Converts T4 → T3 (5'-deiodination, outer ring)
• Also converts T4 → rT3 (5-deiodination, inner ring)
• Inhibited by: PTU, amiodarone, critical illness, selenium deficiency

Type 2 Deiodinase (D2):

• Location: Brain, pituitary, brown adipose tissue, skeletal muscle
• Function: Converts T4 → T3 locally (intracellular T3 generation)
• Critical for: Hypothalamic-pituitary feedback, brain development
• Upregulated in hypothyroidism to maintain local T3

Type 3 Deiodinase (D3):

• Location: Placenta, brain, skin, fetal tissues
• Function: Inactivating enzyme
  • T4 → rT3 (reverse T3, inactive)
  • T3 → T2 (diiodothyronine, inactive)
• Protects fetus from maternal thyroid hormone excess
• Upregulated in critical illness (contributes to low T3)

Cellular Actions of Thyroid Hormones

Nuclear Receptor Mechanism

T3 enters cells via specific transporters (MCT8, MCT10, OATP1C1) and binds nuclear thyroid hormone receptors (TR-α and TR-β). TR-α is predominant in heart, bone, and brain; TR-β is predominant in liver, kidney, and pituitary (PMID: 21515781).

Genomic Effects:

• TR forms heterodimers with retinoid X receptor (RXR)
• Binds thyroid hormone response elements (TREs) in DNA
• Unliganded TR represses transcription
• T3-bound TR activates transcription
• Regulates hundreds of genes involved in metabolism, growth, development

Non-Genomic Effects:

• Plasma membrane effects (ion channels, glucose transport)
• Mitochondrial effects (thermogenesis, oxidative phosphorylation)
• Cytoplasmic signalling (MAPK pathway)

Physiological Effects

Metabolic Rate: T3 increases basal metabolic rate by stimulating Na⁺/K⁺-ATPase activity, mitochondrial oxidative phosphorylation, and substrate cycling. This accounts for thermogenesis and increased oxygen consumption.

Cardiovascular:

• Increases heart rate (chronotropy) via β1-receptor upregulation
• Increases contractility (inotropy) via cardiac myosin genes
• Decreases SVR (peripheral vasodilation)
• Increases cardiac output

Respiratory: Increases ventilatory drive; essential for normal hypoxic and hypercapnic responses.

CNS Development: Essential for normal brain development; deficiency causes cretinism with irreversible mental retardation if not treated in infancy.

Growth: Permissive for GH action; required for normal linear growth. Synergistic with GH for IGF-1 production.

Carbohydrate Metabolism: Increases glucose absorption, gluconeogenesis, and glycogenolysis; may worsen diabetes control.

Lipid Metabolism: Increases LDL receptor expression, cholesterol clearance, and lipolysis. Hypothyroidism causes hypercholesterolaemia.

Regulation of Thyroid Function

TRH → TSH → T4/T3 axis with negative feedback:

• TRH from hypothalamus stimulates TSH release
• TSH binds TSH receptor (Gs-coupled) on thyrocytes
• Increases all steps of thyroid hormone synthesis and release
• T3 inhibits TRH and TSH at hypothalamic and pituitary levels
• T4 is converted to T3 locally in hypothalamus/pituitary by D2

TSH Actions on Thyroid:

• Acute: Increased T4/T3 release from stored thyroglobulin
• Intermediate: Increased iodide uptake, TPO activity, hormone synthesis
• Chronic: Thyroid cell growth and proliferation

The relationship between TSH and free T4 is log-linear: small changes in free T4 cause large changes in TSH. This makes TSH the most sensitive indicator of thyroid status (PMID: 28336049).

---

Euthyroid Sick Syndrome (Non-Thyroidal Illness Syndrome)

Definition and Prevalence

Euthyroid sick syndrome (ESS), also termed non-thyroidal illness syndrome (NTIS), describes the characteristic changes in thyroid function tests seen in critically ill patients without underlying thyroid disease. It is present in 70-80% of ICU patients (PMID: 28336049).

Characteristic Pattern:

• Low T3 (earliest and most consistent finding)
• Normal or low T4 (low in severe/prolonged illness)
• Normal or low TSH (may be mildly elevated in recovery)
• Elevated reverse T3 (rT3)

Pathophysiology

ESS results from multiple mechanisms affecting thyroid hormone production, transport, and metabolism:

Hypothalamic-Pituitary Suppression

Cytokines (IL-1, IL-6, TNF-α) and glucocorticoids inhibit hypothalamic TRH release. TSH pulsatility is reduced, and nocturnal TSH surge is lost. This "central hypothyroidism" of critical illness is mediated by:

• Direct cytokine effects on TRH neurons
• Increased hypothalamic D2 activity (high local T3 suppresses TRH)
• Glucocorticoid suppression of TRH (PMID: 22275474)

Altered Peripheral Conversion

Decreased D1 Activity: Cytokines and hypoxia inhibit D1 in liver and kidney, reducing T4 → T3 conversion. This causes the low T3 that is the hallmark of ESS.

Increased D3 Activity: D3 is upregulated in tissues including skeletal muscle, liver, and inflammatory cells. D3 converts T4 to inactive rT3 and T3 to inactive T2. This explains elevated rT3 in ESS.

The combination of decreased D1 and increased D3 shifts metabolism toward inactivation pathways (PMID: 24297018).

Altered Binding Proteins

Binding proteins (TBG, transthyretin, albumin) decrease in critical illness due to:

• Decreased hepatic synthesis (negative acute phase proteins)
• Increased capillary leak
• Proteolytic cleavage

This decreases total T4 levels but may initially increase free T4. However, some assays measure free T4 inaccurately in the presence of low binding proteins or interfering substances (free fatty acids, heparin).

Other Factors

Medications: Dopamine, glucocorticoids, and amiodarone affect thyroid function tests. Fasting: Reduces TRH and TSH; seen in starvation, anorexia nervosa. Selenium deficiency: Deiodinases are selenoproteins; deficiency impairs T4→T3 conversion.

Clinical Significance

ESS is generally considered an adaptive response to conserve energy during critical illness by reducing metabolic rate. The reduction in T3 decreases oxygen consumption and protein catabolism, potentially providing short-term benefit.

Prognostic Value: Low T4 and T3 levels correlate with illness severity and mortality. A free T4 <0.5 ng/dL or T3 <0.5 ng/dL indicates severe illness with high mortality risk (PMID: 25580018).

Treatment Considerations

Current Recommendation: Do NOT treat euthyroid sick syndrome with thyroid hormone replacement.

Evidence Against Treatment:

• RCTs of T4 or T3 replacement have not shown benefit
• Some studies suggest harm (increased mortality, catabolism)
• ESS typically resolves with recovery from the underlying illness

THYROID-RESCUE Trial (PMID: 35766474): Randomised 1,495 mechanically ventilated patients with low T3 (<0.81 ng/mL) to enteral T3 vs placebo. No difference in 28-day mortality (37.5% vs 37.7%) or secondary outcomes. Confirmed that T3 replacement does not improve outcomes in critical illness.

When to Consider Treatment:

• Pre-existing hypothyroidism
• Central hypothyroidism (pituitary disease)
• Myxoedema coma (true hypothyroid emergency)
• Prolonged ICU stay (>2-3 weeks) with persistent low T4/TSH (controversial)

Distinguishing ESS from True Thyroid Disease

The elevated rT3 in ESS (due to increased D3 activity) helps distinguish it from true hypothyroidism where rT3 is normal or low (PMID: 28336049).

---

Critical Illness-Related Corticosteroid Insufficiency (CIRCI)

Definition

CIRCI describes inadequate corticosteroid activity for the severity of illness in critically ill patients. This may result from:

1. Inadequate adrenal cortisol production
2. Tissue resistance to glucocorticoids
3. Failure of feedback regulation

CIRCI occurs in 10-20% of critically ill patients and up to 60% of septic shock patients (PMID: 28848065).

Pathophysiology

Adrenal Dysfunction

Structural Damage: Adrenal haemorrhage (Waterhouse-Friderichsen syndrome), infarction, or infiltration (metastases, infections).

Functional Impairment:

• Cytokines (TNF-α, IL-1, IL-6) inhibit steroidogenic enzymes
• Substrate limitation (HDL-cholesterol delivery impaired)
• ACTH resistance at MC2R receptor

Peripheral Resistance

Glucocorticoid Receptor Dysfunction:

• Decreased GR expression in tissues
• Impaired GR nuclear translocation
• Increased GRβ isoform (dominant negative)
• Cytokine-induced GR resistance

Altered Cortisol Metabolism:

• Decreased CBG (increased free cortisol)
• Increased cortisol clearance (11β-HSD induction)
• Tissue-specific cortisol inactivation

Diagnosis

Diagnosing CIRCI is challenging because:

• Normal cortisol ranges don't apply in critical illness
• CBG changes affect total cortisol interpretation
• Free cortisol assays not widely available
• ACTH stimulation test interpretation is controversial

2017 SCCM/ESICM Guidelines (PMID: 28848065):

For Diagnosis of CIRCI in Septic Shock:

• Random total cortisol <10 µg/dL (275 nmol/L) - consistent with CIRCI
• Delta cortisol <9 µg/dL after 250 µg ACTH - suggests inadequate reserve
• Note: These criteria have limited sensitivity/specificity

Against ACTH Stimulation Test: The 2017 guidelines suggest against using the ACTH stimulation test to guide treatment decisions, as the response did not predict benefit from corticosteroids in major trials (ANNANE, CORTICUS, ADRENAL).

Treatment

Stress-Dose Hydrocortisone: When CIRCI is suspected in septic shock:

• Hydrocortisone 50 mg IV q6h (or 200 mg/day continuous infusion)
• Duration: Until vasopressors weaned, typically 3-7 days
• Taper over 3-5 days if >7 days of therapy

Fludrocortisone: Addition of fludrocortisone 50 µg daily was used in ANNANE 2002 but not in subsequent trials. Current guidelines do not recommend routine fludrocortisone.

Major Trials

ANNANE Trial 2002 (PMID: 12186604):

• Septic shock with vasopressor dependence
• Hydrocortisone 50 mg q6h + fludrocortisone 50 µg daily × 7 days vs placebo
• ACTH stimulation test performed
• Result: Survival benefit in non-responders (delta cortisol ≤9 µg/dL)
• Criticism: Early termination, baseline imbalances

CORTICUS Trial 2008 (PMID: 18184957):

• Septic shock (less severe than ANNANE)
• Hydrocortisone 50 mg q6h × 5 days + taper vs placebo
• Result: Faster shock reversal but no mortality benefit
• ACTH response did not predict benefit

ADRENAL Trial 2018 (PMID: 29347874):

• Largest trial: 3,658 patients with septic shock on vasopressors + ventilation
• Hydrocortisone 200 mg/day continuous infusion × 7 days vs placebo
• Result: No mortality difference (27.9% vs 28.8%)
• Faster shock resolution, earlier liberation from ventilation
• No increased infections or hyperglycaemia

APROCCHSS Trial 2018 (PMID: 29490185):

• Septic shock with high mortality prediction
• Hydrocortisone + fludrocortisone vs placebo
• Result: Mortality reduction (43.0% vs 49.1%)
• Supports combination therapy in severe septic shock

Current Recommendations (SSC 2021, PMID: 34599691):

• Suggest IV corticosteroids for adults with septic shock and ongoing need for vasopressors
• Hydrocortisone 200 mg/day (continuous or 50 mg q6h)
• Weak recommendation, moderate-quality evidence

---

Hormone Permissiveness

Concept

Hormone permissiveness refers to the phenomenon where one hormone enables or enhances the action of another hormone without directly mediating the effect itself. This is clinically important because deficiency of the permissive hormone can impair the action of the effector hormone.

Examples in Critical Care

Cortisol and Catecholamines: Cortisol is permissive for catecholamine action. In adrenal insufficiency, vascular responsiveness to norepinephrine is reduced. Cortisol restores sensitivity by:

• Upregulating α1-adrenergic receptors
• Inhibiting COMT and MAO (catecholamine-degrading enzymes)
• Reducing NO synthesis
• Decreasing prostaglandin production (PMID: 28848065)

This explains why patients with adrenal crisis have refractory hypotension despite high-dose vasopressors, and why hydrocortisone rapidly restores vascular responsiveness.

Thyroid Hormones and Catecholamines: T3 upregulates β-adrenergic receptor expression and sensitises the heart to catecholamine action. Severe hypothyroidism causes reduced cardiac response to catecholamines. Hyperthyroidism causes exaggerated catecholamine sensitivity (tachycardia, tremor, anxiety).

Thyroid Hormones and Growth Hormone: T3 is permissive for GH action and IGF-1 production. Hypothyroid patients have growth failure despite normal GH levels; GH therapy is ineffective without adequate thyroid hormone.

Cortisol and Glucagon: Cortisol is permissive for glucagon's gluconeogenic and glycogenolytic effects. This synergy is important for the counter-regulatory response to hypoglycaemia.

---

ICU Management of Endocrine Emergencies

Adrenal Crisis

Recognition: Refractory hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia, weakness, altered consciousness. Often precipitated by infection, surgery, or trauma in patients with adrenal insufficiency.

Immediate Treatment:

1. Hydrocortisone 100 mg IV bolus, then 50 mg IV q6h (or 200 mg/day continuous)
2. Volume resuscitation with 0.9% saline (2-3 L in first hours)
3. Dextrose if hypoglycaemic
4. Identify and treat precipitant

Note: Do NOT wait for cortisol results before treating if clinical suspicion high. Dexamethasone 4 mg can be used initially if ACTH stimulation test planned (doesn't interfere with cortisol assay).

Thyroid Storm

Recognition: Fever (>38.5°C), tachycardia (often AF), altered mental status, high-output cardiac failure, GI symptoms. Burch-Wartofsky score >45 suggests thyroid storm.

Treatment (Order Matters):

1. Beta-blocker (propranolol 60-80 mg PO q4h or esmolol infusion) - Controls symptoms, inhibits T4→T3
2. Thionamide (PTU 500-1000 mg loading, then 250 mg q4h OR methimazole 20 mg q4h) - Blocks synthesis
3. Iodine (given 1 hour AFTER thionamide - Lugol's solution 8 drops q6h or SSKI 5 drops q6h) - Blocks release
4. Glucocorticoid (hydrocortisone 100 mg q8h) - Blocks T4→T3, treats possible adrenal insufficiency
5. Supportive care - Cooling, hydration, treat precipitant

Myxoedema Coma

Recognition: Hypothermia, bradycardia, hypotension, altered consciousness, hyponatraemia, hypoventilation. Often precipitated by infection, cold exposure, or sedatives.

Treatment:

1. T4 (levothyroxine): 200-400 µg IV loading, then 50-100 µg IV daily
   • OR T3 (liothyronine): 10-20 µg IV q8-12h (faster onset, higher risk)
   • Some use combination T4 + T3
2. Glucocorticoid: Hydrocortisone 100 mg IV q8h (until adrenal insufficiency excluded)
3. Supportive care: Gentle rewarming, mechanical ventilation if needed, avoid sedatives
4. Hyponatraemia: Usually dilutional; fluid restriction; severe (Na <120) may need hypertonic saline

Caution: T4/T3 replacement increases metabolic rate and myocardial oxygen demand; may precipitate arrhythmias or ischaemia in elderly/cardiac patients.

---

SAQ Practice Questions

SAQ 1: Hypothalamic-Pituitary-Adrenal Axis (15 marks)

Stem: A 58-year-old man is admitted to ICU with septic shock secondary to pneumonia. Despite adequate fluid resuscitation and high-dose norepinephrine (0.5 µg/kg/min), his mean arterial pressure remains 55 mmHg.

(a) Describe the hypothalamic-pituitary-adrenal axis, including the hormones involved and their sites of action. (6 marks)

(b) Explain the concept of "hormone permissiveness" in relation to cortisol and catecholamines. (3 marks)

(c) What is critical illness-related corticosteroid insufficiency (CIRCI) and how might it be diagnosed? (3 marks)

(d) Outline the management of suspected CIRCI in this patient, including drug, dose, and duration. (3 marks)

---

Model Answer:

(a) HPA Axis Description (6 marks)

The HPA axis is a hierarchical neuroendocrine system regulating cortisol secretion:

Hypothalamus (paraventricular nucleus):

• Releases CRH (corticotropin-releasing hormone) in response to stress, inflammation, circadian input
• CRH travels via hypothalamic-hypophyseal portal system to anterior pituitary
• Vasopressin (AVP) synergistically enhances ACTH release via V1b receptors

Anterior Pituitary (corticotrophs):

• CRH binds CRH-R1 (Gs-coupled), increasing cAMP
• Stimulates POMC gene transcription and cleavage to ACTH
• ACTH released into systemic circulation

Adrenal Cortex (zona fasciculata):

• ACTH binds MC2R (Gs-coupled), increasing cAMP
• Activates StAR protein and steroidogenic enzymes
• Stimulates cortisol synthesis and release

Negative Feedback:

• Cortisol inhibits CRH release from hypothalamus (long-loop)
• Cortisol inhibits ACTH release from pituitary (long-loop)
• Operates via glucocorticoid receptors (GR) at both sites
• Fast (non-genomic) and slow (genomic) components

(b) Hormone Permissiveness (3 marks)

Cortisol is "permissive" for catecholamine action—it enables/enhances catecholamine effects without directly mediating them:

1. Receptor upregulation: Cortisol increases α1-adrenergic receptor expression
2. Enzyme inhibition: Cortisol inhibits catecholamine-degrading enzymes (COMT, MAO), prolonging catecholamine action
3. Vasodilator inhibition: Cortisol reduces NO synthesis and prostaglandin production

Clinical relevance: In adrenal insufficiency, vasopressor responsiveness is markedly reduced; cortisol replacement rapidly restores vascular sensitivity.

(c) CIRCI Definition and Diagnosis (3 marks)

Definition: Inadequate corticosteroid activity for illness severity, due to:

• Inadequate adrenal cortisol production
• Tissue resistance to glucocorticoids

Diagnosis (SCCM/ESICM 2017):

• Random total cortisol <10 µg/dL (275 nmol/L) suggests CIRCI
• Delta cortisol <9 µg/dL after 250 µg ACTH suggests inadequate reserve
• ACTH stimulation test is NOT recommended to guide treatment decisions
• Clinical diagnosis based on vasopressor-refractory shock

(d) Management (3 marks)

1. Drug: Hydrocortisone (glucocorticoid with mineralocorticoid activity)
2. Dose: 200 mg/day IV
   • 50 mg IV q6h (intermittent) OR
   • 200 mg/24h continuous infusion
3. Duration: Continue until vasopressors no longer required, typically 3-7 days
4. Taper: If >7 days therapy, taper over 3-5 days to avoid rebound
5. Fludrocortisone: Not routinely recommended (hydrocortisone has mineralocorticoid activity at this dose)

---

SAQ 2: Thyroid Hormone Physiology and Euthyroid Sick Syndrome (15 marks)

Stem: A 72-year-old woman is ventilated in ICU Day 10 for ARDS secondary to influenza pneumonia. Thyroid function tests show: TSH 0.8 mU/L (0.4-4.0), free T4 8 pmol/L (10-22), total T3 0.4 nmol/L (1.2-2.7), reverse T3 elevated.

(a) Describe the synthesis and peripheral conversion of thyroid hormones, including the key enzymes involved. (5 marks)

(b) Explain the pathophysiology of euthyroid sick syndrome, relating it to the biochemistry shown. (5 marks)

(c) Should this patient receive thyroid hormone replacement? Justify your answer with reference to evidence. (3 marks)

(d) How would you distinguish euthyroid sick syndrome from true hypothyroidism? (2 marks)

---

Model Answer:

(a) Thyroid Hormone Synthesis and Conversion (5 marks)

Synthesis in Thyroid Follicles:

1. Iodide trapping: Sodium-iodide symporter (NIS) concentrates iodide 20-40× in thyrocytes
2. Oxidation: Thyroid peroxidase (TPO) oxidises iodide using H₂O₂
3. Organification: TPO iodinates tyrosine residues in thyroglobulin → MIT, DIT
4. Coupling: TPO couples iodotyrosines within thyroglobulin:
   • DIT + DIT → T4 (thyroxine)
   • MIT + DIT → T3 (triiodothyronine)
5. Release: TSH-stimulated endocytosis and proteolysis releases T4, T3

Peripheral Conversion (deiodinases):

• T4 is the prohormone (100% from thyroid)
• T3 is the active hormone (20% thyroid, 80% peripheral conversion)
• T3 has 10× greater receptor affinity than T4

(b) Euthyroid Sick Syndrome Pathophysiology (5 marks)

ESS is an adaptive response to critical illness characterised by altered thyroid hormone metabolism:

Mechanisms explaining the biochemistry:

1. Low T3 (0.4 nmol/L):

   • Decreased D1 activity in liver/kidney (inhibited by cytokines, hypoxia)
   • Increased D3 activity (converts T3 → inactive T2)
   • Reduced T4 → T3 conversion

2. Low T4 (8 pmol/L):

   • Decreased TBG, transthyretin, albumin (negative acute phase proteins)
   • Reduced TSH drive (central suppression)
   • Prolonged illness depletes thyroid stores

3. Normal/low TSH (0.8 mU/L):

   • Cytokines suppress hypothalamic TRH release
   • Increased hypothalamic D2 → high local T3 → feedback inhibition
   • Loss of normal pulsatile TSH secretion

4. Elevated reverse T3:

   • D3 converts T4 → rT3 (upregulated in illness)
   • D1 normally clears rT3 → T2 (D1 inhibited)
   • rT3 accumulates

Adaptive Purpose: Reduces metabolic rate and protein catabolism, conserving energy during acute illness.

(c) Treatment Decision (3 marks)

No—thyroid hormone replacement is NOT recommended.

Evidence:

1. THYROID-RESCUE Trial (2022, PMID: 35766474):

   • 1,495 ventilated patients with low T3
   • Enteral T3 vs placebo
   • No difference in 28-day mortality (37.5% vs 37.7%)
   • No benefit in secondary outcomes

2. ESS is an adaptive response; replacement may:

   • Increase metabolic rate and oxygen demand
   • Worsen catabolism
   • Potentially increase mortality

3. ESS typically resolves with recovery from underlying illness

4. Treatment of underlying condition is the priority

(d) Distinguishing ESS from True Hypothyroidism (2 marks)

Key distinguisher: Elevated rT3 in ESS (due to increased D3) vs normal/low rT3 in hypothyroidism.

---

Viva Scenarios

Viva 1: Adrenal Physiology and Steroid Synthesis

Examiner: Please draw and describe the pathways of steroid hormone synthesis in the adrenal cortex.

Candidate: [Draws diagram showing zones and enzymes]

The adrenal cortex has three zones—glomerulosa, fasciculata, and reticularis—each producing different steroids due to zone-specific enzyme expression.

Common Pathway:

• Cholesterol is the precursor for all steroids
• StAR protein transports cholesterol from outer to inner mitochondrial membrane (rate-limiting)
• CYP11A1 (P450scc) converts cholesterol to pregnenolone

Zona Glomerulosa → Aldosterone:

• Expresses CYP11B2 (aldosterone synthase) but NOT CYP17
• Pregnenolone → progesterone (3β-HSD)
• Progesterone → 11-deoxycorticosterone (CYP21A2)
• 11-deoxycorticosterone → corticosterone → aldosterone (CYP11B2)
• Regulated by angiotensin II and potassium, NOT primarily by ACTH

Zona Fasciculata → Cortisol:

• Expresses CYP17 and CYP11B1 but NOT CYP11B2
• Pregnenolone → 17-OH-pregnenolone (CYP17)
• → 17-OH-progesterone (3β-HSD)
• → 11-deoxycortisol (CYP21A2)
• → Cortisol (CYP11B1)
• Regulated by ACTH

Zona Reticularis → Androgens:

• CYP17 17,20-lyase activity predominates
• 17-OH-pregnenolone → DHEA (CYP17 lyase)
• DHEA → DHEA-S (sulfotransferase)
• DHEA → androstenedione (3β-HSD)

---

Examiner: What is the rate-limiting step in cortisol synthesis?

Candidate: The rate-limiting step is the transfer of cholesterol from the outer to inner mitochondrial membrane by StAR (Steroidogenic Acute Regulatory) protein. This step is acutely regulated by ACTH, which rapidly increases StAR expression and activity.

CYP11A1 (cholesterol side-chain cleavage) is the first enzymatic step and is often considered rate-limiting for the enzymatic pathway itself, but StAR-mediated substrate delivery is the true bottleneck under physiological conditions.

---

Examiner: How does congenital adrenal hyperplasia (21-hydroxylase deficiency) present?

Candidate: 21-hydroxylase (CYP21A2) deficiency is the most common form of CAH (>90% of cases). The enzyme is required for both cortisol and aldosterone synthesis.

Consequences:

1. Cortisol deficiency → Loss of negative feedback → High ACTH → Adrenal hyperplasia
2. Aldosterone deficiency → Salt-wasting (severe forms)
3. Precursor accumulation → Shunted to androgen pathway → Hyperandrogenism

Clinical Presentations:

• Classic salt-wasting (severe): Adrenal crisis in first weeks of life, ambiguous genitalia in females
• Classic simple virilising: Virilisation without salt-wasting
• Non-classic (mild): Late-onset, hirsutism, oligomenorrhoea in females

Diagnosis: Elevated 17-hydroxyprogesterone (precursor before block)

---

Examiner: Explain the clinical importance of 11β-HSD2.

Candidate: 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) is crucial for mineralocorticoid receptor specificity.

The Problem: Cortisol has equal affinity for the mineralocorticoid receptor (MR) as aldosterone but circulates at 100-1000× higher concentrations. Without a protective mechanism, cortisol would overwhelm MR in aldosterone target tissues.

The Solution: 11β-HSD2 is expressed in MR target tissues (kidney, colon, salivary glands). It converts cortisol to cortisone, which does NOT bind MR. This allows aldosterone to selectively activate MR.

Clinical Relevance:

1. Liquorice ingestion: Glycyrrhizic acid inhibits 11β-HSD2, causing "apparent mineralocorticoid excess" (hypertension, hypokalaemia, metabolic alkalosis)
2. Congenital 11β-HSD2 deficiency: AME syndrome—severe hypertension, hypokalaemia in childhood
3. Cushing syndrome: High cortisol may overwhelm 11β-HSD2 capacity, causing hypertension and hypokalaemia

---

Viva 2: Thyroid Hormone Actions and Critical Illness

Examiner: Describe the mechanism by which thyroid hormones exert their cellular effects.

Candidate: Thyroid hormones act primarily through nuclear receptors, with additional non-genomic effects:

Nuclear Receptor Mechanism (Genomic):

1. T3 enters cells via specific transporters (MCT8, MCT10, OATP1C1)
2. T3 binds cytoplasmic/nuclear thyroid hormone receptors (TR-α or TR-β)
3. TR forms heterodimers with retinoid X receptor (RXR)
4. TR-RXR binds thyroid hormone response elements (TREs) in DNA
5. Unliganded TR acts as transcriptional repressor
6. T3-bound TR releases corepressors, recruits coactivators
7. Activates transcription of target genes

Key Target Genes:

• Na⁺/K⁺-ATPase (metabolic rate)
• β1-adrenergic receptors (cardiac)
• Uncoupling proteins (thermogenesis)
• LDL receptor (cholesterol metabolism)

Non-Genomic Effects (rapid, seconds to minutes):

• Plasma membrane ion channel modulation
• Mitochondrial effects on oxidative phosphorylation
• Cytoplasmic signalling (MAPK activation)
• Actin polymerisation

---

Examiner: What is the role of deiodinases, and how are they affected in critical illness?

Candidate: Deiodinases are selenoprotein enzymes that regulate local thyroid hormone availability:

Type 1 Deiodinase (D1):

• Location: Liver, kidney, thyroid
• Function: Activating (T4→T3) and inactivating (rT3→T2)
• Provides circulating T3
• In critical illness: DECREASED activity (cytokines, hypoxia) → low T3

Type 2 Deiodinase (D2):

• Location: Brain, pituitary, brown adipose tissue
• Function: Local T4→T3 conversion
• Protects brain and maintains feedback
• In critical illness: May be INCREASED in hypothalamus → high local T3 → suppresses TRH

Type 3 Deiodinase (D3):

• Location: Placenta, brain, peripheral tissues in illness
• Function: Inactivating (T4→rT3, T3→T2)
• In critical illness: INCREASED activity → explains elevated rT3

Net Effect in ESS:

• Decreased D1 + Increased D3 → low T3, high rT3
• This is considered adaptive, reducing metabolic rate

---

Examiner: A patient in septic shock has TSH 0.5 mU/L, free T4 6 pmol/L (low), T3 0.3 nmol/L (low), and elevated rT3. How do you interpret this?

Candidate: This pattern is classic for euthyroid sick syndrome (non-thyroidal illness syndrome):

Interpretation:

1. Low T3: Earliest and most consistent finding; due to decreased D1 and increased D3
2. Low T4: Indicates severe/prolonged illness; due to decreased binding proteins and reduced TSH drive
3. Low-normal TSH: "Inappropriately normal" for the low T4; reflects central suppression by cytokines
4. Elevated rT3: Pathognomonic; due to increased D3 and decreased D1 (which normally clears rT3)

Key Points:

• This is NOT true hypothyroidism requiring treatment
• TSH would be elevated in primary hypothyroidism
• rT3 would be normal/low in true hypothyroidism
• Pattern typically resolves with recovery from illness

Management: Treat the underlying sepsis. Do NOT give thyroid hormone replacement.

---

Examiner: When, if ever, would you treat this patient with thyroid hormone?

Candidate: Generally, I would NOT treat this patient because:

1. ESS is adaptive: Reduces metabolic rate and protein catabolism
2. Evidence doesn't support treatment: THYROID-RESCUE trial showed no benefit of T3 replacement
3. Potential harm: Increased metabolic rate, catabolism, arrhythmias
4. Recovery expected: ESS resolves when underlying illness improves

Exceptions where I might consider treatment:

1. Pre-existing hypothyroidism: Continue or initiate appropriate replacement
2. Clinical myxoedema coma: Hypothermia, severe bradycardia, altered consciousness → this is a different diagnosis requiring urgent T4/T3
3. Central hypothyroidism: Known pituitary disease → may need replacement
4. Prolonged ICU stay (>3-4 weeks) with persistent low T4 and symptoms: Controversial, would discuss with endocrinology

If treating myxoedema coma:

• T4 200-400 µg IV loading, then 50-100 µg daily
• ± T3 10-20 µg IV q8-12h
• Hydrocortisone 100 mg q8h (until adrenal insufficiency excluded)